

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 31/365, 9/00, A61P 3/04</b>		<b>A1</b>	(11) International Publication Number: <b>WO 00/09122</b>
			(43) International Publication Date: 24 February 2000 (24.02.00)
(21) International Application Number: <b>PCT/EP99/05607</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 August 1999 (02.08.99)		<b>Published</b> <i>With international search report.</i>	
(30) Priority Data: 98115311.7 14 August 1998 (14.08.98) EP 99109516.7 12 May 1999 (12.05.99) EP			
(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH).			
(72) Inventors: HUG, Manuela; Obere Schanzstrasse 6A, D-79576 Weil am Rhein (DE). MAERKI, Hans-Peter; Seltisbergerstrasse 75, CH-4059 Basle (CH). MEIER, Marcel; Bahnhofstrasse 11, CH-4133 Pratteln (CH).			
(74) Agent: WITTE, Hubert; Grenzacherstrasse 124, CH-4070 Basle (CH).			
(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING LIPASE INHIBITORS			
(57) Abstract			
<p>Orally administrable pharmaceutical composition containing an inhibitor of gastrointestinal lipase, one (or more) additive(s) of the group consisting of poorly digestible, poorly fermentable, hydrophilic and/or hydrocolloidal food grade thickeners and emulsifiers, and auxiliary excipients.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PHARMACEUTICAL COMPOSITIONS CONTAINING LIPASE INHIBITORS

The present invention relates to pharmaceutical compositions containing an inhibitor of gastrointestinal lipases, one (or more) additive(s) of the group consisting of poorly digestible, poorly fermentable, hydrophilic and/or hydrocolloidal food grade thickeners and emulsifiers, and excipients.

An example of an inhibitor of gastrointestinal lipases is orlistat, previously known as tetrahydrolipstatin or THL. Orlistat reduces the absorption of dietary fat. Its use for the control or prevention of obesity and hyperlipidaemia is described in US patent 4 598 089.

Anal leakage of oil (oily spotting) is an adverse effect which is occasionally observed in patients treated with lipase inhibitors. This phenomenon reflects physical separation of some liquid unabsorbed dietary fat from the bulk of unabsorbable solids in the lower large intestine. This physical separation and thus anal leakage of oil can be prevented with the pharmaceutical compositions of the present invention.

In the US patent 5 447 953 it has been demonstrated that by combining a lipase inhibitor with substantial amounts of water-insoluble crude fibers, the inhibiting effect on fat absorption can be increased. This synergistic effect is likely attributable to acceleration of gastrointestinal transit of food by the water-insoluble fiber component. The consequent shortening of the time period available for fat digestion combined with the reducing effect on lipase activity intensifies the inhibitory effect on fat absorption.

Surprisingly, it has now been found that the separation of unabsorbed oil from the feces and thus anal oil leakage can be reduced or prevented, when a lipase inhibitor such as orlistat is administered in combination with low amounts of one or more poorly digestible, poorly

fermentable, hydrophilic and/or hydrocolloidal food grade thickeners and/or emulsifiers.

The invention is also concerned with the use of poorly digestible, poorly fermentable hydrophilic and/or hydrocolloidal food grade  
5 thickeners and/or emulsifiers for the combined simultaneous, separate or chronologically spaced use with lipase inhibitors, e.g. orlistat, in the treatment of obesity and hyperlipaemia.

The invention is further concerned with the use of the above  
10 thickeners and/or emulsifiers for treating or preventing the syndrome of anal leakage of oil occurring after the administration of a lipase inhibitor, such as orlistat, or after ingestion of food containing poorly absorbable or non-absorbable fats or oils or undigestible oily fat substitutes.

Further examples of lipase inhibitors which can be used in the  
15 scope of the present invention are lipstatin, panclicins, hesperidin, ebelactones, esterastin and their derivatives, and valilactone.

As thickeners there can be cited water soluble natural, synthetic or semisynthetic polysaccharides, such as methylcellulose, xanthan  
20 gum, psyllium seed, ispaghula husk, plantago ovata seeds, karaya gum and mixtures of such compounds:

Methyl cellulose is the methyl ether of cellulose. It is slowly soluble in water, giving a viscous, colloid solution.

Xanthan gum is a biosynthetic hydrocolloidal high molecular weight exopolysaccharide produced by pure culture fermentation of  
25 Xanthomonas campestris. It contains D-glucose, D-mannose, and D-glucuronic acid as the dominant hexose units and is manufactured as the sodium, potassium, or calcium salt.

Psyllium seed husk, seed coat is a source of soluble fibre. It  
30 comprises cellulose containing walls of endosperm, and mucilage containing epidermis of small dried ripe seeds. A colorless transparent mucilage forms upon contact with water.

Ispaghula husk is psyllium hydrophilic mucilloid. It comprises the epidermis and collapsed adjacent layer of *Plantago* species, e.g. *Pl. psyllium*. It swells rapidly upon contact with water to form a stiff mucilage.

5            *Plantago ovata* seeds (seed husk and seed coat) is a source of soluble fibre. It comprises cellulose containing walls of endosperm, and mucilage containing epidermis of small dried ripe seeds. A colorless transparent mucilage forms upon contact with water.

10           Karaya gum is a hydrocolloidal exudate or gum from *Sterculia* species. It forms a homogenous adhesive gelatinous mass upon contact with water.

Examples of these types of thickeners are contained in OTC products and/or food additives, such as:

15           METHOCEL A4M, a trademark of Dow Chemical Co. for a high viscosity methyl cellulose,

             KELTROL TF, a trademark of Merck & Co. Inc., Rahway NJ, for xanthan gum,

             MUCILAR; psyllium seed (*Psyllii seminis testa*), a product of Spirig AG, CH-4622 Egerkingen,

20           METAMUCIL, ispaghula husk (*Ispaghulae testae pulvis*) a product of Procter & Gamble, CH-1211 Geneve 2,

             AGIOCUR, *plantago ovata* seeds, a product of Madaus AG, D-5000 Köln 91,

25           NORMACOL MITE, a trademark of Norgine Ltd., Great Britain, for karaya gum,

             POLY-KARAYA, a trademark of Delalande for karaya gum of Interdelta SA, CH-1701 Fribourg.

30           A further example of a thickener is FIBERCON (polycarbophil), a trademark of Lederle Laboratories Division, American Cyanamid Co., Pearl River NY, for the calcium salt of a synthetic loosely crosslinked hydrophilic resin of the polycarboxylate type.

As emulsifiers which can be utilized in the compositions of the invention, there can be cited saccharose polyesters, such as Ryoto Sugar

Esters, e.g. Ryoto Sugar Ester S-170. Ryoto Sugar Esters are a trade name of Mitsubishi-Kasi Foods Corp., Chuo-Ku, Tokyo 104, for sucrose fatty acid esters. Ryoto Sugar Ester S-170 contains sucrose stearic acid polyesters.

5           Examples of excipients which can be used in the pharmaceutical compositions of the invention are binders, diluents and lubricants, such as AVICEL, polyvinyl pyrrolidone (povidone), talc, stearic acid and sodium stearyl fumarate; sweeteners, such as sorbitol, glucose, 10           saccharose, saccharine-sodium salt and sodium cyclamate; flavour agents, such as passion fruit, citron and limette; flavour enhancers, such as citric acid, monosodium citrate, sodium chloride and chinine sulfate; effervescing agents, such as sodium bicarbonate and tartaric acid; disintegrants, such as sodium starch glycolate; antimicrobial agents, such as p-hydroxybenzoic acid methyl or propyl ester; 15           detergents, such as sodium lauryl sulfate, and colouring agents, such as  $\beta$ -carotene.

          AVICEL essentially comprises microcrystalline cellulose. It is available from FMC Corporation, Pharmaceutical Division, 1735 Market Street, Philadelphia, PA 19103, e.g. as AVICEL RC-591 or 20           CL-611, which are mixtures of microcrystalline cellulose (about 92%) and carboxymethylcellulose sodium (about 8%), AVICEL PH 101 or PH 105, which is microcrystalline cellulose with an average particle size of 50 or 20  $\mu$ , respectively; AVICEL CE-15 a mixture of microcrystalline cellulose and guar gum.

25           As indicated above, anal leakage of oil, occasionally observed with the therapeutic use of lipase inhibitors such as orlistat, can be reduced or prevented with the pharmaceutical compositions of the invention. This is illustrated by the following in vivo experiments:

          Rats maintained on high fat diet were used as model. Inhibition of 30           fat absorption by diet-admixed orlistat provoked anal leakage of liquid oil. However, the amount of oil leakage could not easily be determined. Due to coprophagia and extensive grooming activity the rats distributed the oil to a large extent over their fur. Moreover, this stressful condition of unsuccessful grooming provoked considerable excitation of the

animals. The area of greasy fur increased in proportion to the amount of unabsorbed fat and was reduced by dietary admixture of selected examples of the above defined food additives. However, for reasons of animal care for comparative evaluation of the additives a surrogate parameter was used to assess effects on oil leakage. Following a meal containing orlistat, unabsorbed fat is temporarily stored in the caecum of the rat prior to excretion. The fat is partly present as floating liquid oil, partly associated with unabsorbable solids. In validation studies it could be demonstrated that the effect of food additives to bind and sequester unabsorbed liquid oil in the solid phase of the caecum is a reliable surrogate parameter predictive for a corresponding reduction of subsequent oil leakage.

The high fat basal diet used contained by weight 56% lab chow, 12% glucose and 32% olive oil. Food additives were supplemented at three levels, accounting for 12.4, 4.5 and 1.2% of the composite diet by weight. Control diets were supplemented with a corresponding amount of starch. All diets were moistened with water to a similar consistency to facilitate acceptability by the animals. Groups of 6-7 female rats (body weight: 120-140 g) were allocated to each diet. After dietary adaptation for one week, the rats were fasted for 24 hours and on the subsequent experimental day the diets were supplied as single meal (basal diet: 4.25 g, additives or starch: 0.6, 0.2 and 0.05 g). In order to completely block absorption of oil and thus produce a defined amount of unabsorbed fat a high dose of orlistat (45 mg) was dissolved in the olive oil fraction (1.5 ml) of the meal. The animals were sacrificed three hours after supplying the meal. At this point in time the caecum contained the largest fraction of administered dietary oil. To determine the relative amounts of bound and free oil in the caecum, the caecal contents were centrifuged (2000 g, 30 min) and the lipid content of the oil/water and solid phase was quantitated gravimetrically following extraction with solvent.

The food additives tested in the first experimental series were methylcellulose (MC), Ryoto sugar ester S-170 (RS) and xanthan gum (XG). The fat content of the liquid and solid phases in the caecum was expressed as percentage of the amount of oil supplied with the meal. Mean values for experimental groups fed the additives, as compared to

controls (where the thickening or emulsifying additive was replaced by the corresponding weight of starch(ST)), are shown in the following table. For statistical assessment of the effect of the additives, Student's t-test was used: n.s. =  $p > 0.05$ , \* =  $p < 0.05$ , \*\* =  $p < 0.01$ , \*\*\* =  $p < 0.001$ .

5

Fat content in caecum in % of the amount of oil supplied:

additive	oil phase	solid phase
MC 0.05 g	24.8 <sup>n.s.</sup>	16.8 *
ST 0.05 g	25.4	13.4
MC 0.20 g	17.0 **	29.2 ***
ST 0.20 g	24.6	13.2
MC 0.60 g	5.0 ***	32.9 ***
ST 0.60 g	37.9	9.6
RS 0.05 g	18.3 <sup>n.s.</sup>	13.6 *
ST 0.05 g	23.6	9.0
RS 0.20 g	22.4 <sup>n.s.</sup>	23.3 ***
ST 0.20 g	24.2	11.0
RS 0.60 g	3.1 ***	37.1 ***
ST 0.60 g	15.8	11.9
XG 0.05 g	12.7 ***	20.3 ***
ST 0.05 g	23.6	9.0
XG 0.20 g	1.1 ***	23.2 ***
ST 0.20 g	24.2	11.0
XG 0.60 g	0.7 ***	18.9 ***
ST 0.60 g	23.6	10.9



As mentioned above 0.6, 0.2 and 0.05 g of food additive provided with the test meal correspond to 12.4, 4.5 and 1.2% by weight in the water-free composite diet.

5 The results shown above clearly demonstrate that in animals administered orlistat in combination with an additive according to the invention, the fraction of unabsorbed fat sequestered in the solid phase of the caecum was significantly increased (and liquid oil reduced) in comparison to control animals supplied with a corresponding amount of starch. Accordingly, the additives are effective in reducing or  
10 preventing anal leakage of liquid oil.

Using the same experimental procedure several OTC products containing additives according to the invention as well as water-insoluble crude fiber products were evaluated in a second experimental series. To ensure a relevant comparison of the products their variable  
15 content of active additive or fiber was taken into account. Accordingly, the amount of each product added to the diet was chosen in such a way that all the test meals contained the same amount of active additive or fiber (0.2 g, 4.5% by weight). The results of these experiments are given in the following table:

20 Fat content in caecum in % of the amount of oil supplied:

OTC product	solid phase
AGIOCUR 0.30 g	20 ***
FIBERCON 0.35 g	18 ***
Starch Control 0.20 g	12
NORMACOL MITE 0.32 g	19 **
METAMUCIL 0.41 g	17 **
Starch Control 0.20 g	13
POLY-KARAYA 0.50 g	20 ***
Wheat bran 0.42 g	15 <sup>n.s.</sup>
Oat bran 1.60 g	11 <sup>n.s.</sup>
Starch Control 0.20 g	12

As mentioned above, the weight of OTC products indicated in the table correspond to 0.2 g active thickening or emulsifying additive or water-insoluble fiber.

5           The data demonstrate binding and sequestering of caecal oil and thus efficacy in preventing anal leakage of oil for the OTC compounds AGIOCUR, FIBERCON, METAMUCIL, NORMACOL MITE and POLY-KARAYA. Moreover, the results show as well the superiority of  
 10 additives according to the invention, as exemplified by POLY-KARAYA, over crude water-insoluble fibers, such as oat and wheat bran (no significant effect), which have been proposed in US patent 5 447 953 to improve the inhibitory effect on fat absorption.

15           The compositions of the invention conveniently contain 1 to 300, preferably from 3 to 30 parts by weight of an emulsifier or thickener for 1 part by weight of orlistat or another lipase inhibitor. They conveniently further contain from 1 to 500, preferably from 3 to 200 parts by weight of auxiliary excipients for 1 part by weight of the lipase inhibitor.

20           The compositions of the invention can be in the form of tablets, capsules or liquid formulations, that may be reconstituted from powder,

granules, pellets, standard or effervescent tablets. They can also be formulated as chewable tablets or lozenges. Furthermore, the compositions can also be incorporated into food preparations, such as wafers, crackers or bisquits.

5           The composition of the invention can also be in the form of a commercial pack containing a lipase inhibitor, such as orlistat, and one or more of the above mentioned thickeners and emulsifiers, with instructions for its use for the simultaneous, separate or chronologically spaced use in the treatment of obesity or hyperlipidaemia.

10           For the treatment or prevention of obesity or hyperlipidaemia, a composition of the invention containing from 50 to 500 mg of orlistat or another lipase inhibitor and from 150 mg to 15 g of an emulsifier or thickener can be administered orally once, twice or three times per day.

15           A preferred composition of the invention is a chewable tablet for the treatment of obesity, consisting essentially of orlistat as the active ingredient and of karaya gum as the thickener, wherein the dosage is from 50 to 150 mg of orlistat and from 3 to 30 parts by weight of karaya gum or xanthan gum per 1 part by weight of orlistat, most preferably wherein the dosage is about 60 mg of orlistat and about 1.5 g of karaya  
20           gum or xanthan gum.

          A method of preventing the syndrome of anal leakage of oil occasionally occurring after the oral administration of orlistat, comprises orally administering from 1 to 3 chewable tablets per fat containing main meal, the dosage of each tablet being from 50 to 150  
25           mg of orlistat and from 3 to 30 parts by weight of karaya gum or xanthan gum per 1 part by weight of orlistat. Preferably, this method comprises orally administering orlistat and karaya gum or xanthan gum in a dosage amount of about 100 mg of orlistat and of about 2 g of karaya gum or xanthan gum per fat containing main meal.

30           The following non-limiting examples illustrate pharmaceutical preparations that can be produced in a manner known per se:

Example 1

Powder for reconstitution:

	Orlistat	0.12 g
	Xanthan gum	1.20 g
5	Sorbitol	9.91 g
	AVICEL CL 611	1.20 g
	$\beta$ -Carotene 1% CWS	0.06 g
	Citric acid	0.10 g
	p-Hydroxybenzoic acid methyl ester	0.15 g
10	p-Hydroxybenzoic acid propyl ester	0.03 g
	Flavouring agent (passion fruit)	0.13 g
	AVICEL PH 105	4.00 g
	Monosodium citrate	1.00 g
	Saccharine-sodium salt	<u>0.10 g</u>
15	Total	18.00 g

An oral suspension can be obtained by adding tap-water to the above powder to a volume of about 50 ml.

Example 2

20 Chewable tablets:

	Orlistat	0.060 g
	Karaya gum	1.500 g
	Polyvinyl pyrrolidone	0.750 g
	Sorbitol	0.970 g
25	AVICEL CE-15	1.000 g
	Talc	0.480 g
	Stearic acid (micro-fine powder)	0.240 g
	Total	5.000 g

30 The indicated amounts of orlistat, karaya gum, polyvinyl pyrrolidone, sorbitol and AVICEL CE 15 are mixed and sieved. The talc and stearic acid are sieved and mixed with the above obtained

mixture. The material is then compressed to chewable tablets with a diameter of 2 cm and a weight of 5 g.

### Example 3

5 Pelletized formulation containing an emulsifier:

1. Orlistat pellets:

	Finely milled orlistat	120 mg
	Microcrystalline cellulose	93.6 mg
	Sodium starch glycolate	7.2 mg
10	Sodium lauryl sulfate	7.2 mg
	Povidone	12 mg
	Total	240 mg

For a batch size of 4 kg pellets the following procedure is applied:

15 Sodium lauryl sulfate (120 g) and povidone (200 g) are dissolved in q.s. water. The solution is cooled to 10-15°C → A. Orlistat (2000 g), microcrystalline cellulose (1560 g) and sodium starch glycolate (120 g) are pre-mixed → B.

20 Solution A is given to pre-mix B and kneaded. The resulting material is extruded to spaghettis. This extrudate is spheromized at 700 rpm. The obtained cylinder-shaped wet pellets are dried in a fluidized bed dryer and then sieved. The 0.5-1.25 mm size fractions are collected as orlistat pellets in closed containers.

2. Emulsifier part.

	Ryoto sugar ester S-170	600 mg
25	Microcrystalline cellulose	312 mg
	Sodium starch glycolate	15 mg
	Povidone	15 mg
	Talc	18 mg
	Total	960 mg

30 For a batch size of 16 kg pellets the following procedure is applied:

Sugar ester (10 kg) is liquefied by heating to 60°C.

Microcrystalline cellulose (5.2 kg), sodium starch glycolate (0.4 kg) and povidone (0.4 kg) are added. The mass is kneaded under cooling to room temperature, then extruded through an extrusion plate with nominal  
5 mesh size of 0.7 mm. The fatty extrudate is cut into pieces of 1 mm length and the resulting mass is dusted with talc in a mixer.

Orlistat pellets (2.4 kg) and emulsifier pellets (9.6 kg) are mixed. The mixture is filled into sachets at a fill weight of 1.2 g, corresponding to 120 mg of orlistat and 600 mg of sugar ester.

Claims

1. Orally administrable pharmaceutical composition containing an inhibitor of gastrointestinal lipase, one (or more) additive(s) of the group consisting of poorly digestible, poorly fermentable, hydrophilic and/or hydrocolloidal food grade thickeners and emulsifiers, and auxiliary excipients.

2. A composition as in claim 1, wherein the additive is a poorly digestible, poorly fermentable, hydrophilic and hydrocolloidal food grade thickener.

3. A composition as in claim 2, wherein the food grade thickener comprises methylcellulose, xanthan gum, psyllium seed, ispaghula husk, plantago ovata seeds, karaya gum or mixtures thereof.

4. A composition as in claim 1, wherein the additive is an emulsifier.

5. A composition as in claim 4, wherein the emulsifier is a saccharose polyester.

6. A composition as in claim 2 or 3 comprising 1 to 300 parts by weight of a thickener per 1 part by weight of an inhibitor of gastrointestinal lipase.

7. A composition as in claim 4 comprising 1 to 300 parts by weight of an emulsifier per 1 part by weight of an inhibitor of gastrointestinal lipase.

8. A composition as in any one of claims 1-7, wherein the inhibitor of gastrointestinal lipase is orlistat.

9. The use of one (or more) compound(s) of the group consisting of poorly digestible, poorly fermentable, hydrophilic and/or hydrocolloidal food grade thickeners and emulsifiers for treating or preventing the syndrome of anal leakage of oil occasionally occurring after the administration of an inhibitor of gastrointestinal lipase, such as

orlistat, or after ingestion of food containing poorly absorbable or non-absorbable fats or oils or undigestible oily fat substitutes.

5 10. A composition as in claim 3 or 8, which is a chewable tablet for the treatment of obesity, consisting essentially of orlistat as the active ingredient and of karaya gum or xanthan gum as the thickener, wherein the dosage is from 50 to 150 mg of orlistat and from 3 to 30 parts by weight of karaya gum or xanthan gum per 1 part by weight of orlistat.

10 11. The chewable tablet as in claim 10, wherein the dosage is about 60 mg of orlistat and about 1.5 g of karaya gum or xanthan gum.

15 12. A method of preventing the syndrome of anal leakage of oil occasionally occurring after the oral administration of orlistat, comprising orally administering from 1 to 3 chewable tablets per fat containing main meal, the dosage of each tablet being from 50 to 150 mg of orlistat and from 3 to 30 parts by weight of karaya gum or xanthan gum per 1 part by weight of orlistat.

20 13. A method of preventing the syndrome of anal leakage of oil occasionally occurring after the oral administration of orlistat, comprising orally administering orlistat and karaya gum in a dosage amount of about 100 mg of orlistat and of about 2 g of karaya gum or xanthan gum per fat containing main meal.

\*\*\*



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/05607

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 A61K31/365 A61K9/00 A61P3/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 447 953 A (ISLER DOROTHEA ET AL) 5 September 1995 (1995-09-05) cited in the application column 1, line 31 - line 51 column 2, line 19 - line 38 column 2, line 65 - column 3, line 11 column 3, line 26 - line 58 claims; examples 1,2 ---	1,2,8
X	WO 98 34607 A (HOFFMANN LA ROCHE) 13 August 1998 (1998-08-13) page 2, line 7 - line 28 page 5, line 14 - line 24 claims; examples --- <div style="text-align: center;">-/--</div>	1,2,4,6, 8
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center;">26 November 1999</div>		Date of mailing of the international search report  <div style="text-align: center;">08/12/1999</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <div style="text-align: center;">Epskamp, S</div>

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/05607

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 638 317 A (HOFFMANN LA ROCHE) 15 February 1995 (1995-02-15) page 2, line 1 - line 17 examples B-D ---	1,2
X	CHEMICAL ABSTRACTS, vol. 127, no. 20, 17 November 1997 (1997-11-17) Columbus, Ohio, US; abstract no. 277507, MIZUGUCHI, YOJI: "Nutrient supplement foods containing taheebo extract and natural minerals" XP002123841 abstract & JP 09 252746 A (NIPPON KANKYO YAKUHI K. K., JAPAN) 30 September 1997 (1997-09-30) ---	1,2,4-7
X	CHEMICAL ABSTRACTS, vol. 128, no. 24, 15 June 1998 (1998-06-15) Columbus, Ohio, US; abstract no. 294200, NISHIMURA, TAKAHISA ET AL: "Solubilization of flavonoids, transglycosylation of flavonoids, and flavonoid solutions". XP002123842 abstract & JP 10 101705 A (EZAKI GLICO CO., JAPAN) 21 April 1998 (1998-04-21) ---	1-3
X	WO 92 17077 A (CURTICE BURNS INC) 15 October 1992 (1992-10-15) page 3, line 1 - line 22 page 4, line 33 -page 7, line 13 claims 1-3,6,14; examples 1,3 ---	9
X	US 4 005 195 A (JANDACEK RONALD JAMES) 25 January 1977 (1977-01-25) column 3, line 5 - line 22 column 4, line 31 -column 6, line 27 example 6 ---	9
A	SJÖSTRÖM L, ET AL.: "Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients" THE LANCET, vol. 352, no. 9123, 18 July 1998 (1998-07-18), pages 167-172, XP002123840 ISSN 0140-6736 Methods (pages 167-169) Results: Adverse events (pages 170-171); table 3 -----	1,9,12, 13

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/05607

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 9, 12 and 13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/05607

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5447953 A	05-09-1995	US 5540917 A	30-07-1996
		AU 4139693 A	06-01-1994
		CA 2098167 A	25-12-1993
		EP 0575846 A	29-12-1993
		JP 6062758 A	08-03-1994
		NZ 247927 A	26-09-1995
		ZA 9304351 A	27-12-1993
WO 9834607 A	13-08-1998	AU 6097298 A	26-08-1998
		CA 2258095 A	13-08-1998
		CN 1220600 T	23-06-1999
		CZ 9803528 A	17-02-1999
		EP 0921796 A	16-06-1999
		HR 980057 A	31-12-1998
		NO 985337 A	16-11-1998
		PL 330972 A	21-06-1999
		ZA 9800746 A	05-08-1998
		JP 11255645 A	21-09-1999
EP 0638317 A	15-02-1995	AU 684793 B	08-01-1998
		AU 6883994 A	16-02-1995
		BR 9403170 A	18-04-1995
		CA 2128044 A	06-02-1995
		CN 1106701 A	16-08-1995
		CZ 9401825 A	15-02-1995
		HU 68300 A	28-06-1995
		IL 110510 A	12-03-1999
		JP 2780932 B	30-07-1998
		JP 7053409 A	28-02-1995
		NO 942900 A	06-02-1995
		NZ 264142 A	26-11-1996
		PL 304557 A	06-02-1995
		US 5643874 A	01-07-1997
		ZA 9405673 A	07-02-1995
JP 9252746 A	30-09-1997	NONE	
JP 10101705 A	21-04-1998	NONE	
WO 9217077 A	15-10-1992	US 5294451 A	15-03-1994
		AU 1676792 A	02-11-1992
		CA 2107222 A	30-09-1992
		EP 0577726 A	12-01-1994
		JP 6506113 T	14-07-1994
		US 5366753 A	22-11-1994
		US 5431949 A	11-07-1994
		US 5338564 A	16-08-1994
US 4005195 A	25-01-1977	BE 851328 A	11-08-1977
		CA 1083043 A	05-08-1980
		DE 2705105 A	18-08-1977
		FR 2340737 A	09-09-1977
		GB 1579241 A	19-11-1980
		IE 44458 B	02-12-1981
		IT 1075126 B	22-04-1985
		JP 1491850 C	07-04-1989
		JP 52120131 A	08-10-1977
		JP 63039568 B	05-08-1988

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/05607

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4005195 A		LU 76751 A	19-08-1977
		NL 7701460 A,B,	16-08-1977
		US RE33996 E	14-07-1992
<hr/>			